CVS Health (CVS) has reached a proposed settlement pact with the Federal Trade Commission on insulin pricing, Amina Niasse of Reuters reported. CVS expects the settlement process to conclude in the coming weeks, but said final terms were still pending. Regulators have reportedly said this model incentivizes companies to introduce higher list prices and steer customers to more expensive drugs, driving larger discounts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health close to settlement with FTC, says JPMorgan
- Sonoma announces U.S. retail launch of advanced burn relief hydrogel
- CVS Health put volume heavy and directionally bearish
- CVS Health Adds Veteran Finance Leader to Board
- Novo Nordisk (NVO) Wins FDA Nod for High-Dose Wegovy amid Surging Obesity Drug Demand